Updated:
BioVentrix
BioVentrix, headquartered in Mansfield, Massachusetts, focuses on a single procedure called Revivent Therapy.
BioVentrix
BioVentrix, headquartered in Mansfield, Massachusetts, focuses on a single procedure called Revivent Therapy. The investigational technique is performed by cardiothoracic surgeons under general anesthesia to remodel the left ventricle in patients with scarred anterior heart wall damage. The company's asset is Revivent Therapy, a cardiac remodeling technique designed for heart failure patients with reduced ejection fraction arising from prior heart attack or chronic low blood supply. It treats scar/aneurysm of the anterior wall. The RELIVE clinical trial, a prospective multi-center randomized study of approximately 135 subjects, compares Revivent plus guideline-directed medical therapy to medical therapy alone. The trial is registered on ClinicalTrials.gov. Geographic focus includes the United States and Germany, where 91 German hospitals are now eligible to negotiate full coverage following a reimbursement designation in March 2026 (per firm press release). BioVentrix appointed Carl Byrnes as Chief Financial Officer in May 2026 (per firm press release). The firm also maintains operations in San Ramon, California. No information on team size, additional investment vehicles, or philanthropic structures is publicly available. The firm is a single-asset medical device company with an investigational product in a pivotal clinical trial. Its structural differentiator is the proprietary Revivent procedure itself, a less invasive alternative to traditional open-heart surgery for ventricular restoration.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Mansfield
Corporate office
Mansfield, MA, United States
Additional offices
San Ramon, CA, United States
Principals
Carl Byrnes
Chief Financial Officer
Sector focus
Frequently asked questions
Who leads investment decisions at BioVentrix?
BioVentrix does not publicly disclose its investment team or board members. Carl Byrnes was named CFO in May 2026, but CEO and other leadership roles are not named on the website. The firm may be privately funded, but no investors or AUM are disclosed.
Is BioVentrix structured as a family office or a medical device company?
BioVentrix is a medical device company, not a family office or asset manager. Its operations and value are tied to its proprietary Revivent Therapy and the ongoing RELIVE clinical trial.
What stage of development is Revivent Therapy in?
Revivent Therapy is investigational and currently being evaluated in the RELIVE clinical trial, a prospective multi-center randomized study. The trial enrolls approximately 135 subjects and is registered on ClinicalTrials.gov. The therapy is not yet approved by regulators like the FDA.
How does BioVentrix generate revenue?
BioVentrix has not publicly disclosed revenue sources. As a clinical-stage company with an investigational product, it likely relies on private fundraising, grants, or investor capital to fund its operations.
What geographic markets does BioVentrix operate in?
BioVentrix's headquarters are in Mansfield, Massachusetts, with an office in San Ramon, California. In Europe, the company has secured a reimbursement designation in Germany, making 91 hospitals eligible to negotiate coverage for Revivent Therapy as of March 2026 (per firm press release).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: